Resultado de búsqueda
Hace 2 días · Our company. Every day, our more than 130,000 employees globally are building a world where complex diseases are prevented and cured, treatments are smarter and less invasive—and solutions are personal. At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress.
- How Our Scientific and Evidence-Based Approach to Real-World Evidence Helps Define Patient and Consumer Outcomes
Real-world data are collected routinely in the context of...
- Spotlight on Johnson & Johnson's Bioethics Efforts
The Johnson & Johnson Bioethics Committee is a formal body...
- United States
Johnson & Johnson is restoring the true meaning of...
- Latest News
Johnson & Johnson Highlights Commitment to Transform...
- How Our Scientific and Evidence-Based Approach to Real-World Evidence Helps Define Patient and Consumer Outcomes
Johnson & Johnson is a global leader in innovative medicine and medical technology. It does not refer to any specific person named John or Johnston.
1 de may. de 2024 · Todas las noticias sobre Johnson & Johnson publicadas en EL PAÍS. Información, novedades y última hora sobre Johnson & Johnson. 02 may 2024 | Actualizado 01:23 CEST | Seleccione:
16 de abr. de 2024 · 2024 First-Quarter reported sales growth of 2.3% to $21.4 Billion with operational growth of 3.9%* and adjusted operational growth of 4.0%* Adjusted operational growth excluding COVID-19 Vaccine of 7.7%* 2024 First-Quarter Earnings per share (EPS) increased to $2.20 and adjusted EPS increased to $2.71 or 12.4%* Company increasing the ...
Johnson & Johnson Highlights Commitment to Transform Treatment of Retinal Diseases at ARVO 2024. A collection of stories that highlight the way Johnson & Johnson is making an impact in the lives of its consumers, and the latest press releases from the company.
Get the latest Johnson & Johnson (JNJ) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
19 de abr. de 2024 · In its primary clinical trial, which was conducted in 2020 before the advent of the delta or omicron variants, J&J reported 66.1% efficacy globally in preventing moderate to severe COVID-19 in...
